At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 707 enrolled
Drug / intervention
NAFT-500 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Pedis
In Brief
A Phase 3 clinical trial evaluating NAFT-500, Placebo 2-weeks, and 2 other interventions for Tinea Pedis and Athlete's Foot. Completed, enrolled 707 participants across 17 sites.
Detailed Summary
A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo, when used in subjects with tinea pedis (athlete's foot).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTinea Pedis, Athlete's Foot
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2008
First PostedSep 2008
Primary CompletionAug 2009
Study CompletionDec 2009
TodayJul 2026
First PostedSep 10, 2008
Enrollment StartAug 1, 2008
Primary CompletionAug 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.8 years ago
Interventions
NAFT-500drug
topical cream 1 application every day up to 4 weeks weeks
Placebo 2-weeksdrug
placebo cream 1 application every day for up to 4 weeks
Naftin 1%drug
topical allylamine cream applied once a day for up to 4 weeks
Placebo 4-weeksdrug
topical placebo cream applied once a day for up to 4 weeks